NCT05632133View on ClinicalTrials.gov

The Lacosamide's Effect on Calcitonin Gene-related Peptide in Migraine Patients

PHASE3CompletedINTERVENTIONAL
Enrollment

200

Participants

Timeline

Start Date

June 1, 2022

Primary Completion Date

August 9, 2023

Study Completion Date

August 10, 2023

Conditions
Effect of DrugMigraine Disorders
Interventions
DRUG

Lacosamide 50 MG Oral Tablet

We assessed the serum level of CGRP before and after 3 months of treatment in 100 episodic migraine patients receiving 50 mg lacosamide Bid and Ibuprofen 200-400 mg only during migraine attacks.

DRUG

Ibuprofen 400 mg

We assessed the serum level of CGRP before and after 3 months of treatment in 100 episodic migraine patients receiving Ibuprofen 200-400 mg only during migraine attacks.

Trial Locations (1)

33511

Kafr Elsheikh University Hospital, Kafr ash Shaykh

All Listed Sponsors
lead

Kafrelsheikh University

OTHER